DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Requip (Ropinirole Hydrochloride) - Published Studies

 
 



Requip Related Published Studies

Well-designed clinical trials related to Requip (Ropinirole)

[Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a multi-center, randomized, double-blind and bromocriptine-controlled trial]. [Article in Chinese] [2013]

The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study. [2013]

PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. [2011.06]

Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. [2011.06]

Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. [2011.04]

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. [2010.05.15]

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. [2010.05.15]

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. [2010]

Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. [2009.09]

Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. [2009.05]

Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. [2009.03]

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. [2007.12]

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. [2007.12]

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. [2007.04.03]

A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. [2007.03.15]

The weight of evidence for ropinirole in restless legs syndrome. [2006.10]

Ropinirole is effective in the long-term management of restless legs syndrome: A randomized controlled trial. [2006.10]

Ropinirole treatment for restless legs syndrome. [2006.09]

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. [2006.01]

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. [2005.03]

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. [2004.12]

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. [2004.08.01]

Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. [2004.07]

Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. [2004.04.27]

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. [2004.01]

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. [2003.07]

Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. [2003.01]

Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. [2003]

Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. [2003]

A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. [2002.12]

Ropinirole for the treatment of tremor in early Parkinson's disease. [2002.05]

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. [2002.04]

Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. [2002.02.12]

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. [2000.05.18]

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. [1999.07.22]

The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. [1999.02]

Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease. [1999.02]

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. [1998.10]

Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. [1998.09]

The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. [1998.05]

Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. [1998.04]

A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. [1998.03]

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. [1998.01]

Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. [1998.01]

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. [1997.08]

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. [1996.06]

Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. [1991.10]

Well-designed clinical trials possibly related to Requip (Ropinirole)

Predictors and biomarkers of treatment gains in a clinical stroke trial targeting the lower extremity. [2014]

Drug safety evaluation of rotigotine. [2012]

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. [2011.10]

Milestones in Parkinson's disease therapeutics. [2011.05]

Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. [2010.02]

Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. [2009.12]

Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). [2009.05]

Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. [2004.10]

A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study. [2004.07]

[1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol] [2000.12]

A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist. [1989.10]

Other research related to Requip (Ropinirole)

Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. [2011.06.23]

Sleep Duration and "on" Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release. [2011]

Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study. [2011]

Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. [2011]

Effects of ropinirole on action potential characteristics and the underlying ion currents in canine ventricular myocytes. [2010.09]

Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. [2010.07]

Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole. [2010.06]

Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. [2010.04]

Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. [2010.04]

[Clinical data of the prolonged-release formulation of ropinirole] [2010.03]

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. [2010.02.01]

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. [2010]

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. [2010]

Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. [2009.12]

A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study. [2009.11]

An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease. [2009.10.30]

Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS. [2009.10]

An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease. [2009.09]

A review of ropinirole prolonged release in Parkinson's disease. [2009]

Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults. [2009]

Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. [2008.12]

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. [2008.10]

Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. [2008.10]

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. [2008.10]

Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome. [2008.09]

Initial experience with ropinirole PR (prolonged release). [2008.09]

Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. [2008.09]

Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation. [2008.08.15]

Ropinirole-induced symptomatic sinus node dysfunction. [2008.08]

Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. [2008.07.15]

Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. [2008.05]

Ropinirole treatment for restless legs syndrome. [2008.05]

Ropinirole treatment for restless legs syndrome. [2008.03]

Effectiveness of ropinirole for RLS and depressive symptoms in an 11-year-old girl. [2008.02.19]

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. [2008.01.26]

Side effects of ropinirole in patients with idiopathic Parkinson's disease. [2008]

Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. [2007.12.15]

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. [2007.12.15]

Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease. [2007.12]

Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. [2007.11.15]

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. [2007.11]

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. [2007.10.15]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014